Resources to Help Your Patients Get Started on WAKIX®

Prescribing WAKIX

  • Complete the WAKIX Prescription Referral Form

  • Fax the completed form to WAKIX for You at 1-855-635-8520

  • WAKIX for You will contact your patient directly to help him or her get started on WAKIX

  • For questions about how WAKIX for You can help, contact a Case Manager.

    1-855-WAKIX4U (1-855-925-4948)

WAKIX Prescription Referral Form

WAKIX is available through a select group of specialty pharmacies. To get your patient started, complete and submit the WAKIX Prescription Referral Form to WAKIX for You.

Get the form

Setting Appropriate Patient Expectations

As with any new treatment option, especially one for a chronic disorder, it is important to set patient expectations

  • WAKIX is the first and only histaminergic treatment for patients with excessive daytime sleepiness (EDS) in narcolepsy
  • WAKIX is not a stimulant
  • It may take up to 8 weeks for some patients to achieve a clinical response with WAKIX
  • WAKIX should be taken once daily in the morning upon wakening

WAKIX for You is Here to Help Your Patients

WAKIX for You is a support program to help your patients get started and stay on track with WAKIX® (pitolisant). This program offers individualized support for your patients based on their specific needs.

  • Work with insurance providers to determine coverage for each patient

  • Offer financial assistance programs for eligible patients

  • Coordinates with the specialty pharmacy to ship WAKIX directly to your patients

  • Provides your patients with educational resources, including information about advocacy groups and patient support groups

News and More About WAKIX

Stay up-to-date and get helpful information. Sign up today and get resources sent directly to your inbox.

Register Now

WAKIX Formulary Kit

Healthcare decision-makers, pharmacists, pharmacy and therapeutics committee members, and formulary decision-makers can request to be contacted for information about obtaining a WAKIX formulary kit.

Request Kit


  • WAKIX® is indicated for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy.



  • WAKIX is contraindicated in patients with severe hepatic impairment.

Warnings and Precautions

  • WAKIX prolongs the QT interval; avoid use of WAKIX in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval. Avoid use in patients with a history of cardiac arrhythmias, as well as other circumstances that may increase the risk of the occurrence of torsade de pointes or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and the presence of congenital prolongation of the QT interval.
  • The risk of QT prolongation may be greater in patients with hepatic or renal impairment due to higher concentrations of pitolisant; monitor these patients for increased QTc. Dosage modification is recommended in patients with moderate hepatic impairment and moderate or severe renal impairment (see full prescribing information). WAKIX is not recommended in patients with end-stage renal disease (ESRD).

Adverse Reactions

  • In the placebo-controlled clinical trials conducted in patients with narcolepsy with or without cataplexy, the most common adverse reactions (≥5% and twice placebo) for WAKIX were insomnia (6%), nausea (6%), and anxiety (5%). Other adverse reactions that occurred at ≥2% and more frequently than in patients treated with placebo included headache, upper respiratory infection, musculoskeletal pain, heart rate increased, hallucinations, irritability, abdominal pain, sleep disturbance, decreased appetite, cataplexy, dry mouth, and rash.

Drug Interactions

  • Concomitant administration of WAKIX with strong CYP2D6 inhibitors increases pitolisant exposure by 2.2-fold. Reduce the dose of WAKIX by half.
  • Concomitant use of WAKIX with strong CYP3A4 inducers decreases exposure of pitolisant by 50%. Dosage adjustments may be required (see full prescribing information).
  • H1 receptor antagonists that cross the blood-brain barrier may reduce the effectiveness of WAKIX. Patients should avoid centrally acting H1 receptor antagonists.
  • WAKIX is a borderline/weak inducer of CYP3A4. Therefore, reduced effectiveness of sensitive CYP3A4 substrates may occur when used concomitantly with WAKIX. The effectiveness of hormonal contraceptives may be reduced when used with WAKIX and effectiveness may be reduced for 21 days after discontinuation of therapy.

Use in Specific Populations

  • WAKIX may reduce the effectiveness of hormonal contraceptives. Patients using hormonal contraception should be advised to use an alternative non-hormonal contraceptive method during treatment with WAKIX and for at least 21 days after discontinuing treatment.
  • There is a pregnancy exposure registry that monitors pregnancy outcomes in women who are exposed to WAKIX during pregnancy. Patients should be encouraged to enroll in the WAKIX pregnancy registry if they become pregnant. To enroll or obtain information from the registry, patients can call 1-800-833-7460.
  • The safety and effectiveness of WAKIX have not been established in patients less than 18 years of age.
  • WAKIX is extensively metabolized by the liver. WAKIX is contraindicated in patients with severe hepatic impairment. Dosage adjustment is required in patients with moderate hepatic impairment.
  • WAKIX is not recommended in patients with end-stage renal disease. Dosage adjustment of WAKIX is recommended in patients with moderate or severe renal impairment.
  • Dosage reduction is recommended in patients known to be poor CYP2D6 metabolizers; these patients have higher concentrations of WAKIX than normal CYP2D6 metabolizers.

Please see the Full Prescribing Information for WAKIX.

To report suspected adverse reactions, contact Harmony Biosciences, LLC at 1-800-833-7460 or FDA at 1-800-FDA-1088 or